Recruiting

Spectral CT

Sponsor:

Palo Alto Veterans Institute for Research

Code:

NCT07303725

Conditions

Liver Cancer (Primary and Metastatic)

Renal Cancer

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Study Details

Brief summary:

This is a pilot study to evaluate the feasibility, image quality, and procedural utility of a novel spectral CT technique using Canon Medical's 4D CT system during image-guided interventional oncology procedures

Conditions

Liver Cancer (Primary and Metastatic)

Renal Cancer

Study ID

NCT07303725

Start date

Feb 1, 2025

Status verified date

Mar, 2025

Completion date

Sep 1, 2026

Anticipated

Primary completion date

Feb 1, 2026

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion criteria:

1. Age > or = 18 years
2. Tumor in an area without prior surgical or ablative therapy
3. At least 1 tumor greater than 1.5 cm in greatest diameter

Exclusion criteria:

1. Not eligible for indicated procedure.
2. BMI > 35
3. Prior surgery.

Study Design

Enrollment

30 participants

Anticipated

Interventions and Outcome Measures

Arms

angiography mapping

Hepatocellular carcinoma (HCC) patients undergoing hepatic angiography mapping prior to TARE (N=10)

microwave ablation

percutaneous tumor ablation in patients receiving image-guided tumor ablation using MWA (n=10)

cryoablation

cryoablation (N=10) for primary liver (HCC) or primary kidney tumors (RCC)

Primary outcome measure

  • CT image [ Time Frame: Baseline ]

Central Contacts and Locations

Central contacts

Locations

VA Palo Alto Healthcare System

Recruiting

Palo Alto, California, United States, 94304

Contacts

Principal Investigator:

Sirish Kishore, MD

More Information

Sponsor

Palo Alto Veterans Institute for Research

Last update posted

Dec 26, 2025

Last verified

Mar, 2025

Keywords

  • spectral CT

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by Palo Alto Veterans Institute for Research on 2025-12-26.